4SC Files Marketing Authorisation Application with EMA for Resminostat ...
4SC AG filed a Marketing Authorisation Application with the EMA for resminostat (Kinselby) for CTCL treatment, following positive RESMAIN study results showing significant PFS improvement and manageable side effects. This marks a significant advancement in 4SC's efforts to commercialize resminostat and enhance patient care.
Reference News
4SC AG filed a Marketing Authorisation Application with the EMA for resminostat (Kinselby) for CTCL treatment, following positive RESMAIN study results showing significant PFS improvement and manageable side effects. This marks a significant advancement in 4SC's efforts to commercialize resminostat and enhance patient care.
4SC AG filed a Marketing Authorisation Application with the EMA for resminostat (Kinselby) for CTCL treatment, showing significant improvement in progression-free survival and manageable side effects in the RESMAIN study. CEO Jason Loveridge highlighted this as a key step in de-risking the program and advancing patient treatment.